Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

Nature Reviews Nephrology

Volumn 8, Issue 11, 2012, Pages 643-657

  Zuber, Julien ^a   Fakhouri, Fadi ^b   Roumenina, Lubka T ^c   Loirat, Chantal ^d   Frémeaux Bacchi, Véronique ^e  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; ECULIZUMAB;

ANAMNESIS; C3 GLOMERULOPATHY; CASE STUDY; CLINICAL PRACTICE; COMPLEMENT ACTIVATION; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; GENE MUTATION; GENETIC ASSOCIATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOGENICITY; INFLAMMATORY CELL; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; REVIEW; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT ACTIVATION; GLOMERULONEPHRITIS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MENINGITIS, MENINGOCOCCAL; RECURRENCE;

EID: 84867993256     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.214     Document Type: Review

References (124)

1. Fakhouri, F., Fremeaux-Bacchi, V., Noel, L. H., Cook, H. T. & Pickering, M. C. C3 glomerulopathy: A new classification. Nat. Rev. Nephrol. 8, 494-499 (2010
2. Noris, M. & Remuzzi, G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 1676-1687 (2009
3. Roumenina, L. T. et al. Alternative complement pathway assessment in patients with atypical HUS. J. Immunol. Methods 365, 8-26 (2011
4. de Cordoba, S. R. & de Jorge, E. G. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin. Exp. Immunol. 151, 1-13 (2008
5. Servais, A. et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82, 454-464 (2012
6. Sethi, S. & Fervenza, F. C. Membranoproliferative glomerulonephritis - A new look at an old entity. N. Engl. J. Med. 366, 1119-1131 (2012
7. Rose, K. L. et al. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J. Clin. Invest. 118, 608-618 (2008
8. Gruppo, R. A. & Rother, R. P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 544-546 (2009
9. Nürnberger, J. et al. Eculizumab for atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 542-544 (2009
10. Hillmen, P. The role of complement inhibition in PNH. Hematology Am. Soc. Hematol. Educ. Program 116-123 (2008
11. Hillmen, P. et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355, 1233-1243 (2006
12. Kelly, R. J. et al. Long-Term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival. Blood 117, 6786-6792 (2011
13. Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky R. A. & Bell, L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25, 1256-1264 (2007
14. Electronic Medicines Compendium. Soliris - Summary of Product Characteristics [online], http://www.medicines.org.uk/emc/medicine/19966/SPC/ soliris/ (2012
15. U. S. Food and Drug Administration. Highlights of Prescribing Information: Soliris [online], http://www.accessdata.fda.gov/drugsatfda-docs/ label/2011/125166s172lbl.pdf (2011
16. Simister, N. E. Placental transport of immunoglobulin G. Vaccine 21, 3365-3369 (2003
17. Kelly, R. et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br. J. Haematol. 149, 446-450 (2010
18. Luzzatto, L., Gianfaldoni, G. & Notaro, R. Management of paroxysmal nocturnal haemoglobinuria: A personal view. Br. J. Haematol. 153, 709-720 (2011
19. Forneris, F. et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 330, 1816-1820 (2010
20. Rooijakkers, S. H. et al. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat. Immunol. 10, 721-727 (2009
21. Laursen, N. S. et al. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J. 30, 606-616 (2011
22. Overturf, G. D. Indications for the immunological evaluation of patients with meningitis. Clin. Infect. Dis. 36, 189-194 (2003
23. Ram, S., Lewis, L. A. & Rice, P. A. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin. Microbiol. Rev. 23, 740-780 (2010
24. Brodsky, R. A. et al. Long term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria (PNH). Presented at the 52nd American Society of Hematology Annual Meeting (2010
25. de Jorge, E. G. et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J. Am. Soc. Nephrol. 22, 137-145 (2011
26. Pickering, M. C. et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J. Exp. Med. 204, 1249-1256 (2007
27. Al-Akash, S. I., Almond, P. S., Savell, V. H. Jr, Gharaybeh S. I. & Hogue, C. Eculizumab induces long-Term remission in recurrent post-Transplant HUS associated with C3 gene mutation. Pediatr. Nephrol. 26, 613-619 (2011
28. Ardissino, G. et al. Remission of plasma-resistant atypical hemolytic uremic syndrome relapse on kidney graft with eculizumab. Presented at the 2nd International Conference on HUS-MPGN-PNH (2010
29. Ariceta, G., Arrizabalaga, B., Aguirre, M., Morteruel, E. & Lopez-Trascasa, M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am. J. Kidney Dis. 59, 707-710 (2012
30. Chatelet, V., Fremeaux-Bacchi, V., Lobbedez, T., Ficheux, M. & de Ligny B. H. Safety and long-Term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am. J. Transplant. 9, 2644-2645 (2009
31. Chatelet, V. et al. Eculizumab: Safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: Case report. Transplant. Proc. 42, 4353-4355 (2010
32. Dorresteijn, E. M., van de Kar, N. C. & Cransberg, K. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Pediatr. Nephrol. 27, 1193-1195 (2012
33. Durán, C. E., Blasco, M., Maduell, F. & Campistol, J. M. Rescue therapy with eculizumab in a transient recipient with atypical haematologic-uraemic syndrome. Clin. Kidney J. 5, 28-30 (2012
34. Kim, J. J., Waller S. C. & Reid, C. J. Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis. Clin. Kidney J. 5, 34-36 (2012
35. Lapeyraque, A. L., Frémeaux-Bacchi, V. & Robitaille, P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr. Nephrol. 26, 621-624 (2011
36. Larrea, C. F. et al. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 89, 903-904 (2010
37. Malina, M. et al. Peripheral gangrene in children with atypical hemolytic uremic syndrome. Presented at the 44th Annual Meeting of the European Society for Pediatric Nephrology (2011
38. Nester, C. et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 6, 1488-1494 (2011
39. Ohanian, M., Cable, C. & Halka, K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin. Pharmacol. 3, 5-12 (2011
40. Prescott, H. C., Wu, H. M., Cataland, S. R. & Baiocchi, R. A. Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. Am. J. Hematol. 85, 976-977 (2010
41. Tschumi, S., Gugger, M., Bucher, B. S., Riedl, M. & Simonetti, G. D. Eculizumab in atypical hemolytic uremic syndrome: Long-Term clinical course and histological findings. Pediatr. Nephrol. 26, 2085-2088 (2011
42. Weitz, M., Amon, O., Bassler, D., Koenigsrainer, A. & Nadalin, S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr. Nephrol. 26, 1325-1329 (2011
43. Zimmerhackl, L. B. et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 362, 1746-1748 (2010
44. Fremont, O. T., Gordon, C. A. & Hand, M. M. Eculizumab treatment for aHUS in a child with positive family history. Presented at the 42nd Annual Meeting of the American Society of Nephrology (2009
45. Garjau, M. et al. Early treatment with eculizumab may be beneficial in atypical haemolytic uraemic syndrome. Clin. Kidney J. 5, 31-33 (2012
46. Haffner, K., Hofer, J., Zimmerhackl, L. B. & Pohl, M. Effective eculizumab therapy of familiar atypical HUS in a 4 year old patient. Presented at the 2nd International Conference on HUS, MPGN and PNH (2010
47. Kose, O., Zimmerhackl, L. B., Jungraithmayr, T., Mache C. & Nurnberger, J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin. Thromb. Hemost. 36, 669-672 (2010
48. Mache, C. J. et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 4, 1312-1316 (2009
49. Davin, J. C. et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am. J. Kidney Dis. 55, 708-711 (2010
50. Heyne, N. Terminal complement blockade by eculizumab effectively reverses recurrent atypical hemolytic uremic syndrome after kidney transplantation. Presented at the 44th Annual Meeting of the American Society of Nephrology (2011
51. Legault, D. & Boelkins, M. Successful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with the terminal complement inhibitor eculizumab. Presented at the 51st Annual Meeting of the American Society of Hematology (2009
52. Zuber, J. et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat. Rev. Nephrol. 7, 23-35 (2011
53. European Medicines Agency. Soliris [online], http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/000791/human-med-001055. jsp&mid=WC0b01ac058001d124 (2012
54. Simonetti, G. D. Eculizumab therapy for atypical hemolytic uremic syndrome in pediatric patients: Efficacy and safety outcomes from retrospective study. Presented at the 44th Annual Meeting of the European Society for Pediatric Nephrology (2011
55. Krid, S. et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am. J. Transplant. 12, 1938-1944 (2012
56. Koskinen, A. R. et al. Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome. Am. J. Transplant. 11, 1885-1895 (2011
57. Lonze, B. E., Singer, A. L. & Montgomery, R. A. Eculizumab and renal transplantation in a patient with CAPS. N. Engl. J. Med. 362, 1744-1745 (2010
58. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01029587 (2011
59. Stegall, M. D. et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 11, 2405-2413 (2011
60. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01399593 (2012
61. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00844545 (2011
62. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00838513 (2011
63. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00844844 (2011
64. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00844428 (2011
65. Legendre, C. et al. Safety and efficacy of eculizumab in aHUS resistant to plasma therapy: Interim analysis from a phase II trial. Presented at the 43rd Annual Meeting of the American Society of Nephrology (2010
66. Greenbaum, L. A. et al. Continued improvement in renal function with sustained eculizumab in patients with atypical HUS resistant to plasma exchange/infusion. Presented at the 44th Annual Meeting of the American Society of Nephrology (2011
67. Greenbaum, L. A. et al. Eculizumab is an effective long-Term treatment in patients with atypical hemolytic uremic syndrome resistant to plasma exchange/infusion: Results of an extension study. Presented at the 53th Annual Meeting of the American Society of Hematology (2011
68. Licht, C. et al. Eculizumab is an effective long-Term treatment in patients with atypical haemolytic uremic syndrome previously receiving chronic plasma exchange/infusion: Extension study results. Presented at the 53th Annual Meeting of the American Society of Hematology (2011
69. Licht, C. et al. Phase II study of eculizumab in patients with atypical HUS receiving chronic plasma exchange/infusion. Presented at the 44th Annual Meeting of the American Society of Nephrology (2011
70. Muus, P. et al. Safety and efficacy in aHUS patients on chronic plasma therapy: Interim analysis of a phase II trial. Presented at the 43rd Annual Meeting of the American Society of Nephrology (2010
71. Loirat, C., Saland, J. & Bitzan, M. Management of hemolytic uremic syndrome. Presse Med. 41, e115-e135 (2012
72. Zipfel, P. F., Heinen, S. & Skerka, C. Thrombotic microangiopathies: New insights and new challenges. Curr. Opin. Nephrol. Hypertens. 19, 372-378 (2010
73. Coppo, P. et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: The French TMA reference center experience. Plos ONE 5, e10208 (2010
74. Ferrari, S. et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 109, 2815-2822 (2007
75. George, J. N. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 116, 4060-4069 (2010
76. Scully, M. et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 118, 1746-1753 (2011
77. Noris, M. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5, 1844-1859 (2010
78. Sellier-Leclerc, A. L. et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 18, 2392-2400 (2007
79. Lapeyraque, A. L. et al. Eculizumab in severe Shiga-toxin-associated HUS. N. Engl. J. Med. 364, 2561-2563 (2011
80. Hadaya, K. et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am. J. Transplant. 11, 2523-2527 (2011
81. Shapira, I., Andrade, D., Allen, S. L. & Salmon, J. E. Induction of durable remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 64, 2719-2723 (2012
82. Chapin, J., Weksler, B., Magro, C. & Laurence, J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br. J. Haematol. 157, 772-774 (2012
83. Réti, M. et al. Complement activation in thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 10, 791-798 (2012
84. Trachtman, H., Austin, C., Lewinski, M. & Stahl, R. A. K. Renal and neurological involvement in typical Shiga toxin-Associated HUS. http://dx.doi.org/10.1038/nrneph.2012.196.
85. Fakhouri, F. et al. Pregnancy-Associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J. Am. Soc. Nephrol. 21, 859-867 (2010
86. Le Quintrec, M. et al. Complement mutation-Associated de novo thrombotic microangiopathy following kidney transplantation. Am. J. Transplant. 8, 1694-1701 (2008
87. Chandran, S., Baxter-Lowe, L., Olson, J. L., Tomlanovich, S. J. & Webber, A. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation - A case report. Transplant. Proc. 43, 2097-2101 (2011
88. Wilson, C. H. et al. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 92, e42-e43 (2011
89. Fakhouri, F. et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 112, 4542-4545 (2008
90. Fang, C. J., Richards, A., Liszewski, M. K., Kavanagh, D. & Atkinson, J. P. Advances in understanding of pathogenesis of aHUS and HELLP. Br. J. Haematol. 143, 336-348 (2008
91. Salmon, J. E. et al. Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort. Plos Med. 8, e1001013 (2011
92. Boyer, O. et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am. J. Kidney Dis. 55, 923-927 (2010
93. Dragon-Durey, M. A. et al. Clinical features of anti-factor H autoantibody-Associated hemolytic uremic syndrome. J. Am. Soc. Nephrol. 21, 2180-2187 (2010
94. Kwon, T. et al. Successful pre-Transplant management of a patient with anti-factor H autoantibodies-Associated haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 23, 2088-2090 (2008
95. Le Quintrec, M. et al. Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am. J. Transplant. 9, 1223-1229 (2009
96. Moore, I. et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115, 379-387 (2010
97. Ariceta, G. et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr. Nephrol. 24, 687-696 (2009
98. Taylor, C. M., Machin, S., Wigmore, S. J. & Goodship, T. H. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br. J. Haematol. 148, 37-47 (2010
99. Michon, B. et al. Complications of apheresis in children. Transfusion 47, 1837-1842 (2007
100. Witt, V. et al. World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry. Transfus. Apher. Sci. 39, 255-260 (2008
101. Som, S. et al. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion http://dx.doi.org/10.1111/j.1537-29952012. 03646.x.
102. Roumenina, L. T. et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain-of-function. Blood 119, 4182-4191 (2012
103. Sallee, M. et al. Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol. Dial. Transplant. 25, 2028-2032 (2010
104. Loirat, C. et al. Non-Atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrol. Dial. Transplant. 10, 3421-3425 (2010
105. Vergouwen, M. D., Adriani, K. S., Roos, Y. B., Groothoff, J. W. & Majoie, C. B. Proximal cerebral artery stenosis in a patient with hemolytic uremic syndrome. AJNR Am. J. Neuroradiol. 29, e34 (2008
106. Bienaime, F. et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int. 77, 339-349 (2010
107. Kvarnstrom, A. L., Sarbinowski, R. T., Bengtson, J. P., Jacobsson, L. M. & Bengtsson, A. L. Complement activation and interleukin response in major abdominal surgery. Scand. J. Immunol. 75, 510-516 (2012
108. Neher, M. D., Weckbach, S., Flierl, M. A., Huber-Lang, M. S. & Stahel, P. F. Molecular mechanisms of inflammation and tissue injury after major trauma - is complement the "bad guy"? J. Biomed. Sci. 18, 90 (2011
109. Marasca, R. et al. Pregnancy in PNH: Another eculizumab baby. Br. J. Haematol. 150, 707-708 (2010
110. Loirat, C. & Fremeaux-Bacchi, V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr. Transplant. 12, 619-629 (2008
111. Zuber, J. et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am. J. Transplant. http://dx.doi.org/10. 1111/j.1600-6143.2012.04252.x.
112. Saland, J. M., Ruggenenti P. & Remuzzi, G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 20, 940-949 (2009
113. Hegasy, G. A., Manuelian, T., Hogasen, K., Jansen, J. H. & Zipfel, P. F. The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: Point mutations in the factor H coding sequence block protein secretion. Am. J. Pathol. 161, 2027-2034 (2002
114. Pickering, M. C. et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat. Genet. 31, 424-428 (2002
115. Little, M. A., Dupont, P., Campbell, E., Dorman, A. & Walshe, J. J. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-Transplantation recurrence risk. Kidney Int. 69, 504-511 (2006
116. Fakhouri, F. et al. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int. 78, 279-286 (2010
117. Pickering, M. C. et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc. Natl Acad. Sci. USA 103, 9649-9654 (2006
118. Bomback, A. S. et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin. J. Am. Soc. Nephrol. 7, 748-756 (2012
119. Daina, E., Noris, M. & Remuzzi, G. Eculizumab in a patient with dense-deposit disease. N. Engl. J. Med. 366, 1161-1163 (2012
120. Radhakrishnan, S. et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N. Engl. J. Med. 366, 1165-1166 (2012
121. Vivarelli, M., Pasini, A. & Emma, F. Eculizumab for the treatment of dense-deposit disease. N. Engl. J. Med. 366, 1163-1165 (2012
122. McCaughan, J. A., O'Rourke D. M. & Courtney, A. E. Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies. Am. J. Transplant. 12, 1046-1051 (2012
123. Herlitz, L. C. et al. Pathology after eculizumab in dense deposit disease and C3 GN. J. Am. Soc. Nephrol. 23, 1229-1237 (2012
124. Bouts, A., Monnens, L., Davin, J. C., Struijk, G. & Spanjaard, L. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr. Nephrol. 26, 1919-1920 (2011